Cantor Fitzgerald Lowers PT to $5, Reiterates Overweight Rating on PAVmed (PAVM)
Tweet Send to a Friend
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating while lowering the price target on PAVmed (NASDAQ: PAVM) to $5 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
